SCIENTIFIC PROGRAMME
SESSION I
HOW I TREAT
SMOLDERING MYELOMA
(SMM)
SESSION II
HOW I TREAT NEWLY
DIAGNOSED MULTIPLE
MYELOMA
SESSION III
FROM RISK
STRATIFICATION TO
RISK-BASED THERAPY?
DEBATE 1
SHOULD WE USE MRD
TESTING TO DETERMINE
THERAPY IN MULTIPLE
MYELOMA?
DEBATE 2
IS THERE A FUTURE ROLE
OF AUTOLOGOUS STEM
CELL TRANSPLANTATION?
SESSION IV
HOW I TREAT RELAPSED
MULTIPLE MYELOMA
DEBATE 3
SHOULD EVERY PATIENT
RECEIVE DARATUMUMAB
IN FIRST LINE?
ROUNDTABLE
MULTIPLE MYELOMA
FROM THE PERSPECTIVE
OF FDA/EMEA AND
FOUNDATIONS
SESSION V
YOU CAN’T BE IMMUNE
FOR IMMUNE THERAPY
ANYMORE
SESSION VI
OTHER PLASMA CELL
DYSCRASIAS
KEYNOTE LECTURES
THE FUTURE OF
MULTIPLE MYELOMA
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
ABSTRACTS SELECTED
AS POSTERS
DISCLOSURES
Suggested lectures
- Dimopoulos MA, Moreau P, Terpos E, Mateos M-V, Zweegman S, Cook G, et al. Multiple
Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up.
HemaSphere. 2021 Feb;5(2):e528.
- Siegel DS, Dimopoulos MA, Ludwig H, Facon T, Goldschmidt H, Jakubowiak A, et al. Improvement
in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With
Relapsed or Refractory Multiple Myeloma. J Clin Oncol Off J Am Soc Clin Oncol. 2018
Mar;36(8):728–34.
- Bahlis NJ, Dimopoulos MA, White DJ, Benboubker L, Cook G, Leiba M, et al. Daratumumab plus
lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up
of POLLUX, a randomized, open-label, phase 3 study. Leukemia. 2020 Jul;34(7):1875–84.
- Mateos M-V, Sonneveld P, Hungria V, Nooka AK, Estell JA, Barreto W, et al. Daratumumab,
Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With
Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR. Clin Lymphoma
Myeloma Leuk. 2020 Aug;20(8):509–18.
- Dimopoulos M, Quach H, Mateos M-V, Landgren O, Leleu X, Siegel D, et al. Carfilzomib,
dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with
relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre,
open-label, phase 3 study. Lancet (London, England). 2020 Jul;396(10245):186–97.
- Dimopoulos MA, Lonial S, White D, Moreau P, Weisel K, San-Miguel J, et al. Elotuzumab,
lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3
randomized ELOQUENT-2 study. Blood Cancer J. 2020 Sep;10(9):91.
- Orlowski RZ, Moreau P, Niesvizky R, Ludwig H, Oriol A, Chng WJ, et al. Carfilzomib-
Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple
Myeloma: Updated Overall Survival, Safety, and Subgroups. Clin Lymphoma Myeloma Leuk. 2019
Aug;19(8):522-530.e1.
- Dimopoulos MA, Weisel KC, Moreau P, Anderson LD, White DJ, San-Miguel J, et al. Pomalidomide
+ Bortezomib + Low-Dose Dexamethasone after 1 Prior Line of Therapy in Patients with
Lenalidomide-Pretreated Multiple Myeloma: Subanalysis of the Phase 3 Optimismm Trial By
Patient Age and Prior Stem Cell Transplant. Blood Internet. 2019 Nov
13;134(Supplement_1):3120. Available from: https://doi.org/10.1182/blood-2019-124349